ValorQ4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses1.6 M1.69 M1.54 M1.33 M6.16 MResearch & development7.61 M5.35 M4.73 M5.04 M22.74 MOperating income-8.34 M-5.41 M-5.42 M-6.37 M-25.54 MNon-Operating Income, Total81.75 K47.52 K49.12 K54.3 K232.69 KInterest expense, net of interest capitalized00000Non-Operating Income, excl. Interest Expenses81.75 K47.52 K49.12 K54.3 K232.69 KUnusual income/expense—————Pretax income-8.26 M-5.36 M-5.37 M-6.32 M-25.31 MEquity in earnings—————Taxes—000—Non-controlling/minority interest—————After tax other income/expense—————Net income before discontinued operations-8.26 M-5.36 M-5.37 M-6.32 M-25.31 MDiscontinued operations—————Net income-8.26 M-5.36 M-5.37 M-6.32 M-25.31 MDilution adjustment—————Preferred dividends—————Diluted net income available to common stockholders-8.26 M-5.36 M-5.37 M-6.32 M-25.31 MBasic earnings per share (Basic EPS)13.75-11.25-8.75-7.75-14Diluted earnings per share (Diluted EPS)-39.82-11.2-8.74-7.79-67.55Average basic shares outstanding207.48 K478.19 K614.37 K811.49 K2.11 MDiluted shares outstanding207.48 K478.19 K614.37 K811.49 K2.11 MEBITDA-8.32 M-5.39 M-5.4 M-6.36 M-25.47 MEBIT-8.34 M-5.41 M-5.42 M-6.37 M-25.54 MCost of revenue—————Other cost of goods sold—————Depreciation & amortization (cash flow)21.64 K16.92 K16.8 K16.8 K72.17 K
GeoVax Labs Inc
GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles in the person being vaccinated.